This Is Why with Dr. Busti

SGLT2 inhibitors (bexagliflozin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) don’t just lower glucose and A1C, but these meds have become relevant in cardiovascular disease and chronic kidney disease in the right patients also with type 2 diabetes (T2DM). In this lecture from This is Why, Dr. Busti will make the SGLT2 inhibitors make sense as they provide cardiorenal protection above their improvements in A1C.

You’ll learn how to:

- Mechanism of action (MOA): how SGLT2 blockade drives glucosuria, modest A1c reduction, weight loss, and BP lowering

- Clinical use: where SGLT2 inhibitors fit for type 2 diabetes, plus major outcomes in heart failure and chronic kidney disease (CKD) (cardiorenal protection is a key reason they’re prioritized in modern guidelines)

- Key drugs (for exams + real-world practice): Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana), Ertugliflozin (Steglatro), and Bexagliflozin (Brenzavvy)

- Adverse effects & safety pearls: genital mycotic infections, volume depletion/hypotension, AKI considerations, and the “don’t-miss” rare events like euglycemic DKA (plus how to recognize it)

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin-diabetes-pharmacology-review

Get more with a free membership at https://www.thisiswhy.health/

- Access free downloads from our videos 

- Access deep dive content from Dr. Busti

- Organize content via playlists & collections

- Join live Q&A

- Receive member newsletters

- Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#sglt2inhibitors #empagliflozin #type2diabetes #diabetespharmacology #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Meglitinides (Nateglinide & Repaglinide) can feel like the “forgotten” oral diabetes drugs—but they show up on exams, in real-world medication histories, and in questions about postprandial glucose control and hypoglycemia and weight gain risk. In this lecture from This is Why, Dr. Busti will explain the meglitinides in a clear, clinically relevant way so you can recognize them quickly and use the concepts confidently in the context of Type 2 diabetes (T2DM).

You’ll learn how to:

- Meglitinides overview: where they fit in type 2 diabetes (T2DM) therapy

- Drug names you must know: repaglinide and nateglinide

- Mechanism of action: how these insulin secretagogues stimulate insulin release (the KATP channel connection)

- Onset/duration & dosing concept: why they’re considered short-acting / prandial glucose agents

- Therapeutic application: targeting postprandial hyperglycemia and when they may (or may not) be chosen

- Adverse effects & safety: hypoglycemia, weight considerations, and key patient counseling points

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/meglitinides-repaglinide-nateglinide-diabetes-pharmacology-review

Get more with a free membership at https://www.thisiswhy.health/

- Access free downloads from our videos 

- Access deep dive content from Dr. Busti

- Organize content via playlists & collections

- Join live Q&A

- Receive member newsletters

- Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#meglitinides #repaglinide #nateglinide #type2diabetes #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Insulin doesn’t have to be confusing when learning how to treat Type 1 and Type 2 diabetes mellitus. In this lecture from This is Why, Dr. Busti will explain how to quickly recognize insulin types, predict onset/peak/duration, and apply basal–bolus dosing concepts to real-world Type 1 and Type 2 diabetes care.

You’ll learn how to:

- How to identify rapid-, short-, intermediate-, and long-acting insulin for Diabetes

- The difference between basal insulin vs bolus (mealtime) insulin

- How basal–bolus regimens work (plus common pitfalls)

- Practical tips for insulin administration, timing with meals, and avoiding errors

- High-yield clinical points you’re likely to see in courses and on exams

Insulins covered (for memorization + exam success):

- Rapid-acting: insulin lispro, aspart, glulisine

- Short-acting: regular insulin

- Intermediate-acting: NPH insulin

- Long-acting / basal: insulin glargine, detemir, degludec

- Premixed options: 70/30 mixes (NPH/regular and related premixed products)

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/insulin-types-diabetes-pharmacology-review

Get more with a free membership at https://www.thisiswhy.health/

- Access free downloads from our videos 

- Access deep dive content from Dr. Busti

- Organize content via playlists & collections

- Join live Q&A

- Receive member newsletters

- Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#insulin #diabetes #insulintypes #diabetespharmacology #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Understand the GLP-1 receptor agonists—and why agents like semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide, dulaglutide, and exenatide have become one of the most talked-about type 2 diabetes medications in modern practice. In this lecture from This is Why, Dr. Busti will break GLP-1s down in a clear, clinically relevant way so you can confidently explain how they work, when to use them, and what to watch for clinically when managing patients with type 2 diabetes and/or obesity.

You’ll learn how to:

- Mechanism of action: incretin mimetic effects (GLP-1) and what that means for glucose control

- Therapeutic use: where GLP-1 agonists fit in type 2 diabetes (T2DM) treatment strategies

- Key agents: semaglutide, plus comparisons to liraglutide, dulaglutide, and exenatide

- Benefits & counseling pearls: weight effects, dosing basics, and practical patient education

- Adverse effects & precautions: the high-yield safety points clinicians get tested on (and seen in clinical practice)

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/glp-1-receptor-agonists-semaglutide-dulaglutide-liraglutide-diabetes-pharmacology-review

Get more with a free membership at https://www.thisiswhy.health/

- Access free downloads from our videos 

- Access deep dive content from Dr. Busti

- Organize content via playlists & collections

- Join live Q&A

- Receive member newsletters

- Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#glp1receptoragonist #semaglutide #type2diabetes #diabetesmedications #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Tirzepatide (Mounjaro/Zepbound)—the dual incretin GIP/GLP-1 agonist—is a beneficial treatment of type 2 diabetes and/or obesity.  In this lecture from This is Why, Dr. Busti will break down how tirzepatide works (MOA), why combining GIP + GLP-1 improves A1C reduction and supports weight loss, and where it fits in the treatment of type 2 diabetes. You’ll also get the high-yield points you need for exams and the bedside: tirzepatide dosing basics, common adverse effects, contraindications/precautions, and practical tips for patient counseling (nausea, GI effects, injection technique, and expectations).

You’ll learn how to:
- Tirzepatide overview: Mounjaro vs Zepbound
- GIP/GLP-1 agonist mechanism (dual incretin)
- Clinical use in type 2 diabetes
- A1C lowering + weight loss effects
- Adverse effects, warnings, and counseling pearls

The goal = make medical education easy and clinically relevant.

👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/tirzepatide-mounjaro-zepbound-gip-glp1-agonist-type-2-diabetes-pharmacology

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#tirzepatide #mounjaro #gipglp1 #type2diabetes #busti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will learn about the application of DPP-4 inhibitors in the management of type 2 diabetes mellitus (T2DM). The DPP-4 inhibitors (e.g., sitagliptin, linagliptin, saxagliptin) have an impact of incretins (GIP, GLP-1) which have continued to evolve in other treatment options.

You’ll learn how to:
- Mechanism of action: DPP-4 inhibition and impact on incretins (GLP-1/GIP) 
- Key drugs: Sitagliptin, linagliptin, saxagliptin
- Clinical role: where DPP-4 inhibitors fit in type 2 diabetes treatment, including add-on therapy
- Adverse effects & safety pearls: the side effects and warnings you need to know for exams and practice

The goal = make medical education easy and clinically relevant.

👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/dpp-4-inhibitors-sitagliptin-type-2-diabetes-pharmacology

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#dpp4inhibitors #type2diabetes #sitagliptin #diabetespharmacology #busti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Metformin is a first-line oral medication for type 2 diabetes.  In this lecture from This is Why, Dr. Busti will explain how metformin works to lower the A1c and help patients with type 2 diabetes get to their A1C goals. 

You’ll learn how to:
- Metformin mechanism of action (MOA): how biguanides lower glucose and improve insulin resistance
- Where metformin fits in type 2 diabetes therapy (first-line option and combination use)
- Key clinical benefits (A1C lowering, weight neutrality/possible weight loss)
- Dosing basics and titration strategies (including extended-release considerations)
- High-yield adverse effects: GI effects, vitamin B12 concerns, and the real story on lactic acidosis
- Contraindications and precautions (renal function, acute illness, contrast studies, alcohol use)
- Monitoring and patient counseling points you should know for practice and exam

The goal = make medical education easy and clinically relevant.

👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/metformin-biguanide-type-2-diabetes-pharmacology

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#metformin #type2diabetes #diabetespharmacology #biguanide #busti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Amylin Analogs (Pramlintide) for Diabetes: Pharmacology Made Easy.  In this lecture from This is Why, Dr. Busti will explain how pramlintide (Symlin/SymlinPen) works and when it’s used as an adjunct to insulin for type 1 diabetes (and select type 2 diabetes cases). In this diabetes pharmacology review, I break down the mechanism of action of an amylin analog, why it helps postprandial glucose control, and the key clinical pearls you need for exams and practice.

You’ll learn how to:
- What amylin does physiologically and how pramlintide mimics it
- How pramlintide lowers post-meal blood glucose (slows gastric emptying, suppresses glucagon, increases satiety)
- How to use pramlintide with mealtime insulin (timing + dose adjustment concepts)
- Adverse effects & safety: nausea, hypoglycemia risk, and major counseling points

The goal = make medical education easy and clinically relevant.

👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/amylin-analogs-pramlintide-diabetes-pharmacology

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#pramlintide #amylinanalog #diabetespharmacology #type1diabetes #busti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

In this lecture from This is Why, Dr. Busti will teach you about Alpha-Glucosidase Inhibitors for Diabetes — the pharmacology made easy breakdown of acarbose and miglitol for type 2 diabetes.

You’ll learn how to:
- Explain how alpha-glucosidase inhibitors reduce postprandial hyperglycemia
- Identify where these drugs work (GI tract) and why they don’t cause hypoglycemia by themselves
- Compare acarbose vs miglitol (what’s similar, what’s different)
- Recognize common GI adverse effects (e.g., flatulence, diarrhea, abdominal discomfort)
- Know when they are (and are not) used in type 2 diabetes medications
- Apply patient counseling: timing with meals + what to do if hypoglycemia occurs on combination therapy

The goal = make medical education easy and clinically relevant.

👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/alpha-glucosidase-inhibitors-acarbose-miglitol-type-2-diabetes-pharmacology

👉 Get more with a free membership at https://www.thisiswhy.health/
- Access free downloads from our videos 
- Access deep dive content from Dr. Busti
- Organize content via playlists & collections
- Join live Q&A
- Receive member newsletters
- Coupons & discounts for exam prep resources

👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#alphaglucosidaseinhibitors #acarbose #miglitol #type2diabetespharmacology #busti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Statins (HMG-CoA Reductase Inhibitors) are the foundation of LDL lowering and ASCVD prevention. In this lecture from This is Why, Dr. Busti will make statin pharmacology easy to understand, but also clinically relevant in the proper context of the evidence. The use of HMG CoA reductase inhibitors: atorvastatin, rosuvastatin, simvastatin, pitavastatin, and pravastatin are drugs in this drug class that Dr. Busti will review. 

You’ll learn how to:

• MOA: How HMG-CoA reductase inhibitors reduce hepatic cholesterol synthesis and increase LDL clearance
• Clinical uses: Hyperlipidemia treatment, primary prevention, and secondary prevention for ASCVD
• High-yield statins: Atorvastatin, rosuvastatin, simvastatin, pravastatin (and how to think about intensity)
• Adverse effects: Statin myopathy, muscle pain/weakness, and rare rhabdomyolysis
• Key interactions: CYP3A4 interactions (especially with certain statins) and what to watch for clinically
• Pearls for exams: How to connect lipid lowering drugs to patient cases and test questions

The goal = make medical education easy and clinically relevant.

Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/statins-hmg-coa-reductase-inhibitors-ldl-lowering

Get more with a free membership at https://www.thisiswhy.health/

• Access free downloads from our videos 
• Access deep dive content from Dr. Busti
• Organize content via playlists & collections
• Join live Q&A
• Receive member newsletters
• Coupons & discounts for exam prep resources

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#statins #hmgcoareductaseinhibitors #ldllowering #lipidloweringdrugs #busti

Disclaimer:

This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.